BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32865695)

  • 21. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression.
    Zhu J; Zou Z; Nie P; Kou X; Wu B; Wang S; Song Z; He J
    Cell Death Dis; 2016 Nov; 7(11):e2454. PubMed ID: 27809310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
    Kim SS; Lee MH; Lee MO
    Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapamycin enhances the sensitivity of ER‑positive breast cancer cells to tamoxifen by upregulating p73 expression.
    Zhu L; Li XX; Shi L; Wu J; Qian JY; Xia TS; Zhou WB; Sun X; Zhou XJ; Wei JF; Ding Q
    Oncol Rep; 2019 Jan; 41(1):455-464. PubMed ID: 30542717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
    Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
    Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing
    Zhang P; Yang Y; Qian K; Li L; Zhang C; Fu X; Zhang X; Chen H; Liu Q; Cao S; Cui J
    J Biol Chem; 2020 Oct; 295(41):14140-14152. PubMed ID: 32690611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
    Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
    BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arsenic‑induced BRCA1 CpG promoter methylation is associated with the downregulation of ERα and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
    Selmin OI; Donovan MG; Skovan B; Paine-Murieta GD; Romagnolo DF
    Int J Oncol; 2019 Mar; 54(3):869-878. PubMed ID: 30664189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
    Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
    Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
    Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS
    Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
    Santiago-Gómez A; Kedward T; Simões BM; Dragoni I; NicAmhlaoibh R; Trivier E; Sabin V; Gee JM; Sims AH; Howell SJ; Clarke RB
    Cancer Lett; 2019 Aug; 458():66-75. PubMed ID: 31121213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CUL4B renders breast cancer cells tamoxifen-resistant via miR-32-5p/ER-α36 axis.
    Wang Y; Pan X; Li Y; Wang R; Yang Y; Jiang B; Sun G; Shao C; Wang M; Gong Y
    J Pathol; 2021 Jun; 254(2):185-198. PubMed ID: 33638154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.
    Cittelly DM; Finlay-Schultz J; Howe EN; Spoelstra NS; Axlund SD; Hendricks P; Jacobsen BM; Sartorius CA; Richer JK
    Oncogene; 2013 May; 32(20):2555-64. PubMed ID: 22751119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.
    Bekele RT; Venkatraman G; Liu RZ; Tang X; Mi S; Benesch MG; Mackey JR; Godbout R; Curtis JM; McMullen TP; Brindley DN
    Sci Rep; 2016 Feb; 6():21164. PubMed ID: 26883574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.